Vantage Hemp Co. Initiates European Regulatory Filings for Pharmaceutical-Grade CBD
Key Insights
Vantage Hemp Co. (search) has initiated submissions for Certificate of Suitability (CEP) and Active Substance Master File (ASMF) to European regulatory agencies, positioning itself among the first global manufacturers pursuing formal recognition for hemp-derived pharmaceutical ingredients.
The company partnered with German life sciences firm WELDING GmbH & Co. KG (search) to expand pharmaceutical-grade CBD access across the European Union, European Economic Area, Switzerland, India, and North Macedonia.
These regulatory filings follow Europe's introduction of harmonized pharmacopoeial standards for cannabidiol in July 2024 and the issuance of the first European CEP for CBD extract in early 2025.
Vantage Hemp Co. (search), a globally accredited cannabinoid manufacturer based in Greeley, Colorado, has initiated the submission process for its Certificate of Suitability (CEP) to the European Directorate for the Quality of Medicines (search) (EDQM) and its Active Substance Master File (ASMF) to the European Medicines Agency (search) (EMA). These applications position Vantage among the first global manufacturers pursuing formal regulatory recognition for hemp-derived active pharmaceutical ingredients (APIs) under Europe's newly harmonized pharmacopoeial standard for cannabidiol (CBD).
Strategic Partnership Expands European Access
To support access and distribution, Vantage has partnered with WELDING GmbH & Co. KG (search), a family-owned life sciences company headquartered in Hamburg, Germany, with over 70 years of experience in pharmaceutical sourcing, registration, and supply chain management. Through WELDING's established distribution network and Vantage's internationally recognized manufacturing standards, the two companies can meet the demand for pharmaceutical-grade materials across the European Union, the European Economic Area, Switzerland, India, and North Macedonia.
Regulatory Milestone Advances Market Position
The CEP and ASMF applications mark a significant milestone in advancing the Company's position as a global CBD supplier. The CEP will confirm that Vantage's CBD isolate meets all European pharmacopoeial quality standards, simplifying regulatory approvals and accelerating time-to-market for European pharmaceutical partners.
The ASMF will strengthen the Company's leadership position by enabling pharmaceutical developers to use Vantage's CBD isolate in finished drug formulations while protecting Vantage's proprietary data. The process streamlines marketing authorization applications across Europe, providing a clear and compliant route for cannabinoid-based medicines.
"These filings will benefit companies wanting to develop CBD-based pharmaceuticals," says Deepank Utkhede, Chief Operating Officer and Chief Process Biochemist at Vantage. "They enable us to expand into clinical and commercial applications, support our pharmaceutical partners with a clear regulatory path, and pave the way for pharmaceutical-grade CBD to be accessed safely, reliably, and consistently."
Building on Recent Regulatory Clarity
Vantage and WELDING's partnership builds on a recent wave of regulatory clarity across Europe. The introduction of harmonized pharmacopoeial standards in July 2024 and the issuance of the first European CEP for a CBD extract in early 2025 have established a clearer, faster, and more uniform path for pharmaceutical-grade cannabinoids.
Manufacturing Standards and Certifications
Vantage Hemp Co. (search) operates under FDA 21 CFR 210/211, ICH Q7, PIC/S, and WHO GMP standards, producing CBD and CBG (search) APIs that meet international pharmacopeial specifications. The company's operations are certified by Australia's Therapeutic Goods Administration (search) (TGA) and include active submissions with ANVISA (Brazil).
Representatives from Vantage and WELDING will be attending CPHI Frankfurt 2025 to meet with existing and prospective partners to discuss ongoing regulatory developments and European expansion plans.